Eco-Growth Strategies Inc. (ECGS) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $3.08M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerEco-Growth Strategies Inc. (ECGS) trades at $0.054. Eco-Growth Strategies Inc. (ECGS) is a healthcare-focused company specializing in drug manufacturing, particularly in specialty and generic drugs. Market cap: $3.08M, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for ECGS: ECGS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ECGS against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
ECGS: 1/2 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Eco-Growth Strategies Inc. (ECGS) Healthcare & Pipeline Overview
Eco-Growth Strategies Inc. (ECGS) operates in the healthcare sector, focusing on the production of specialty and generic drugs, leveraging innovative technologies to enhance patient care and meet diverse market needs.
What Is the Investment Thesis for ECGS?
Eco-Growth Strategies Inc. ECGS's commitment to research and development is expected to yield new product offerings, enhancing its market share and revenue streams. Key value drivers include its established distribution channels and partnerships with healthcare providers, which facilitate market penetration. However, potential risks include regulatory challenges and competition from established players. ECGS's ability to innovate and adapt to market changes will be crucial for its sustained growth and profitability.
Based on FMP financials and quantitative analysis
ECGS Key Highlights
Market Cap: $3.08M, indicating a current lack of market valuation due to trading on OTC markets.
- Beta: -3.97, suggesting high volatility in relation to the market.
- Dividend Yield: None, reflecting the company's reinvestment strategy in growth initiatives.
- Focus on specialty and generic drugs, tapping into a market projected to grow significantly over the next few years.
- Established presence in Northern California, serving a diverse range of clients in the healthcare sector.
Who Are ECGS's Competitors?
ECGS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MCK McKesson Corporation | $880.90 | +0.00% | $103B | 885-pillar |
| ABC AmerisourceBergen Corporation | $179.98 | -0.23% | $36.2B | — |
| CI Cigna Corporation | $280.91 | +0.99% | $74.2B | 805-pillar |
| CVS CVS Health Corporation | $95.29 | -0.09% | $122B | 695-pillar |
| WBA Walgreens Boots Alliance, Inc. | $11.98 | +0.50% | $10.4B | — |
| GELS Gelteq Limited Ordinary Shares | $0.79 | -7.37% | $7.23M | — |
| COSM COSM | $0.25 | -0.71% | $13.8M | — |
| BFRI Biofrontera Inc. | $1.59 | +9.25% | $20.4M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ECGS's Key Strengths?
Strong focus on specialty pharmaceuticals with high growth potential.
- Established manufacturing capabilities ensuring product quality.
- Diverse product portfolio addressing various therapeutic areas.
- Experienced leadership team with industry expertise.
What Are ECGS's Weaknesses?
Limited market presence outside of Northern California.
- Dependence on regulatory approvals for new product launches.
- Challenges in scaling operations to meet growing demand.
- Lack of brand recognition compared to larger competitors.
What Could Drive ECGS Stock Higher?
Launch of new specialty drug products aimed at addressing specific health conditions.
- Expansion of distribution partnerships with healthcare providers to enhance market access.
- Increased investment in R&D expected to yield innovative drug formulations.
- Navigating regulatory approvals for new products to facilitate market entry.
- Strategic initiatives to enter emerging markets with high demand for pharmaceuticals.
What Are the Key Risks for ECGS?
Financial-distress signal — its Altman Z-Score of -48.00 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory changes that could impact drug approval timelines.
- Competition from larger pharmaceutical companies with established market presence.
- Pricing pressures from healthcare providers seeking cost-effective solutions.
- Market volatility affecting the company's growth strategy.
What Are the Growth Opportunities for ECGS?
- Expansion into Emerging Markets: Eco-Growth Strategies Inc. is poised to expand its footprint in emerging markets where demand for affordable healthcare solutions is on the rise. The global pharmaceutical market in emerging economies is projected to grow at a CAGR of 10% through 2025. By establishing distribution partnerships and local manufacturing capabilities, ECGS can tap into these lucrative markets, enhancing its revenue potential.
- Development of Specialty Drugs: The company is focusing on the development of specialty drugs that target specific diseases, which are expected to account for nearly 50% of total pharmaceutical sales by 2025. This strategic focus allows ECGS to benefit from higher margins and reduced competition, as specialty drugs often face fewer generic alternatives.
- Investment in R&D: ECGS plans to increase its investment in research and development to foster innovation and develop new drug formulations.
- Strategic Partnerships: Forming strategic alliances with healthcare providers and research institutions can enhance ECGS's product development capabilities and market reach. Collaborations can lead to shared resources and expertise, accelerating the time-to-market for new products and improving competitive positioning.
- Regulatory Approvals and Market Access: Successfully navigating the regulatory landscape to obtain approvals for new drugs can significantly impact ECGS's growth trajectory. With the increasing focus on expedited approval processes by regulatory agencies, ECGS can leverage this trend to bring its innovative products to market more quickly.
What Are ECGS's Competitive Advantages?
- Strong focus on R&D allows for innovation and development of unique drug formulations.
- Established relationships with healthcare providers enhance market access.
- Compliance with stringent regulatory standards builds trust with clients.
- Ability to produce both specialty and generic drugs diversifies revenue streams.
- Operational efficiencies in manufacturing contribute to cost leadership.
What Does ECGS Do?
Eco-Growth Strategies Inc. (ECGS) is a healthcare company based in Rancho Cordova, California, primarily engaged in the manufacturing of specialty and generic pharmaceuticals. Founded with the mission to improve healthcare access and affordability, ECGS has evolved to become a significant player in the drug manufacturing industry. The company specializes in developing a range of pharmaceutical products that cater to various therapeutic areas, addressing critical health needs while ensuring compliance with stringent regulatory standards. Over the years, ECGS has expanded its capabilities, focusing on research and development to innovate and enhance its product offerings. The firm is committed to quality, utilizing advanced technologies and methodologies in its manufacturing processes to ensure the efficacy and safety of its drugs. ECGS serves a diverse clientele, including hospitals, pharmacies, and healthcare providers, aiming to improve patient outcomes through its high-quality pharmaceutical products. The company's strategic focus on specialty drugs positions it well within a growing segment of the market, as these products often command higher margins and are less susceptible to competition from generic alternatives. As ECGS continues to navigate the complexities of the healthcare landscape, it remains dedicated to its core values of integrity, innovation, and excellence in service delivery.
What Products and Services Does ECGS Offer?
- Manufacture specialty pharmaceuticals targeting specific health conditions.
- Produce generic drugs to provide cost-effective treatment options.
- Engage in research and development to innovate new drug formulations.
- Ensure compliance with regulatory standards in drug manufacturing.
- Provide high-quality pharmaceuticals to healthcare providers and pharmacies.
- Focus on enhancing patient care through effective medication solutions.
How Does ECGS Make Money?
- Generate revenue through the sale of specialty and generic pharmaceuticals.
- Leverage partnerships with healthcare providers for distribution.
- Invest in R&D to develop new drug offerings and improve existing products.
- Utilize a direct sales model to reach hospitals and pharmacies.
- Implement cost-effective manufacturing processes to maintain competitive pricing.
What Industry Does ECGS Operate In?
The drug manufacturing industry, particularly in the specialty and generic segments, is experiencing significant growth, driven by rising healthcare expenditures and an increasing emphasis on cost-effective treatment options. The global market for generic drugs is expected to expand substantially, fueled by patent expirations of blockbuster drugs and the increasing acceptance of generics by healthcare professionals and patients alike. Within this competitive landscape, Eco-Growth Strategies Inc. (ECGS) is strategically positioned to leverage its manufacturing capabilities and innovative product development to capture market share. The ongoing shift towards personalized medicine and specialty pharmaceuticals presents additional growth opportunities for ECGS, as these products often address unmet medical needs and command premium pricing.
Who Are ECGS's Key Customers?
- Hospitals seeking high-quality pharmaceuticals for patient care.
- Pharmacies looking for reliable suppliers of generic drugs.
- Healthcare providers requiring specialized medications for specific conditions.
- Government contracts for supplying pharmaceuticals in public health initiatives.
- Educational institutions involved in healthcare training and research.
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 73 days ago
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 47 |
| 2026-08-26 | 47 |
| 2026-08-29 | 47 |
| 2026-09-01 | 47 |
| 2026-09-04 | 47 |
| 2026-09-07 | 47 |
| 2026-09-10 | 47 |
What changed?
The score has stayed at 47.
Over the same 18 days the stock moved +14.2%.
Company Profile
Eco-Growth Strategies Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Rancho Cordova, US. The company is led by CEO William J. Delgado. ECGS has traded publicly since 2021.
Key Financial Metrics
Return on equity for Eco-Growth Strategies Inc. stands at 10.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -75.4%, showing how much profit it generates from its asset base. Its free cash flow yield is 71.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.58 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -21.5%, the inverse of the P/E and a quick read on earnings relative to price.
ECGS Valuation & Market Position
With a $3.08M market cap, Eco-Growth Strategies Inc. sits in the micro-cap segment of the market.
Quarterly Financial Performance: Eco-Growth Strategies Inc.
Revenue for Eco-Growth Strategies Inc. came in at $0 during Q2 FY2026. The company recorded a net loss of $159K, with diluted EPS of $-0.00. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, ECGS averaged $-0.01 in diluted EPS.
Financial Health
Eco-Growth Strategies Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -48.00 places it in the distress zone, a signal of elevated financial risk.
ECGS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Strong focus on specialty pharmaceuticals with high growth potential.
- Established manufacturing capabilities ensuring product quality.
- Diverse product portfolio addressing various therapeutic areas.
- Experienced leadership team with industry expertise.
Bear Case
- Limited market presence outside of Northern California.
- Dependence on regulatory approvals for new product launches.
- Challenges in scaling operations to meet growing demand.
- Lack of brand recognition compared to larger competitors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · June 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $0 | -$158,961 | -$0.0028 |
| Q1 FY2026 | $0 | -$335,878 | -$0.01 |
| Q4 FY2025 | $0 | -$606,761 | -$0.01 |
| Q1 FY2025 | $0 | -$522,499 | -$0.01 |
Q2 FY2026 · filed 30 Jun 2026 · Financial Modeling Prep
Based on FMP financials and quantitative analysis
ECGS Latest News
No recent news available for ECGS.
ECGS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ECGS.
Price Targets
Wall Street price target analysis for ECGS.
ECGS MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ECGS; grades run from A+ (80-100) to F (below 30).
Leadership: William J. Delgado
CEO
William J. Delgado has over 20 years of experience in the pharmaceutical industry, holding various leadership roles in both manufacturing and R&D. He holds a Master's degree in Pharmaceutical Sciences from a leading university and has a proven track record in driving operational excellence and product innovation.
Track Record: Under William's leadership, ECGS has expanded its product portfolio and improved operational efficiencies, leading to increased revenue and market presence. His strategic vision has positioned the company to capitalize on emerging opportunities in the healthcare sector.
ECGS OTC Market Information
The OTC Other tier indicates that Eco-Growth Strategies Inc. is not listed on major exchanges like NYSE or NASDAQ, which may result in lower visibility and liquidity compared to larger companies. Stocks in this tier often face challenges in attracting institutional investors due to less stringent reporting requirements.
- OTC Tier: OTC Other
- Limited liquidity can lead to higher volatility and price fluctuations.
- Potential lack of transparency due to minimal reporting requirements.
- Increased risk of fraud or mismanagement in smaller OTC companies.
- Difficulty in attracting institutional investment due to lower visibility.
- Verify the company's financial health through available reports.
- Assess the management team's experience and track record.
- Evaluate the competitive landscape and market positioning.
- Investigate the regulatory environment affecting the company.
- Examine growth opportunities and potential risks.
- Established leadership team with industry experience.
- Commitment to regulatory compliance in drug manufacturing.
- Partnerships with reputable healthcare providers.
ECGS Healthcare Stock FAQ
Is ECGS a good stock?
Stock Expert AI does not rate ECGS buy, sell or hold. Eco-Growth Strategies Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What does Eco-Growth Strategies Inc. do?
Eco-Growth Strategies Inc. specializes in the manufacturing of specialty and generic pharmaceuticals. The company focuses on developing innovative drug formulations to meet diverse healthcare needs while ensuring compliance with regulatory standards.
What are the key factors to evaluate for ECGS?
Evaluate ECGS on fundamentals, analyst consensus, and risk factors. Eco-Growth Strategies Inc. ECGS's commitment to research and development is expected to yield new product offerings, enhancing its market share and revenue streams. Not financial advice.
How frequently does ECGS data refresh on this page?
ECGS's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 calculations are scheduled daily at 10:15 UTC; the score's own date shows its last successful run.
What has driven ECGS's recent stock price performance?
Eco-Growth Strategies Inc. (ECGS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong focus on specialty pharmaceuticals with high growth potential. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ECGS overvalued or undervalued right now?
Eco-Growth Strategies Inc. (ECGS) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ECGS?
Yes, most major brokerages offer fractional shares of Eco-Growth Strategies Inc. (ECGS) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ECGS's earnings and financial reports?
Eco-Growth Strategies Inc. (ECGS) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for ECGS earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited financial transparency due to OTC classification.